Novagali Pharma Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 50

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Latest Deal Amount
  • $4.34M

  • Investors
  • 1

Novagali Pharma General Information

Description

Operator of a pharmaceutical company committed to developing and commercializing ophthalmic innovative products for all segments of the eye. The company specializes in the research, development, testing, production, and marketing of emulsion drugs that address the numerous needs of patients suffering from ocular conditions, thereby helping ophthalmologists to improve the lives of their patients.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 1 Rue Pierre Fontaine
  • Genavenir IV, Evry Cedex
  • 91058 Paris
  • France
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • 1 Rue Pierre Fontaine
  • Genavenir IV, Evry Cedex
  • 91058 Paris
  • France

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novagali Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Secondary Transaction - Private 06-Jan-2012 $4.34M Completed Generating Revenue
7. Merger/Acquisition 11-Oct-2011 Completed Generating Revenue
6. IPO 21-Jul-2010 Completed Generating Revenue
5. Grant 01-Apr-2010 Completed Generating Revenue
4. Later Stage VC (Series D) 26-Sep-2009 Completed Generating Revenue
3. Later Stage VC (Series C) 01-Apr-2006 Completed Generating Revenue
2. Early Stage VC (Series B) 20-Sep-2004 $17.3M $21.1M Completed Generating Revenue
1. Early Stage VC (Series A) 01-Jan-2000 $3.84M $3.84M Completed Product Development
To view Novagali Pharma’s complete valuation and funding history, request access »

Novagali Pharma Patents

Novagali Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20080107738-A1 Cationic ophthalmic oil-in-water type emulsion; colloid particles, oily core surrounded by interfacial film; poloxamers, tyloxapol non ionic surfactant; prostaglandin is latanoprost, unoprostone isopropyl; chitosan, chlorhexidine, benzalkonium halide, vegetable oils; eye drops, ointment, ophthalmic gel Active 09-Nov-2004

Novagali Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Novagali Pharma Former Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
123 Investment Managers Asset Manager Minority
Andera Partners PE/Buyout Minority
Auriga Partners (Paris) Venture Capital Minority
Bpifrance Sovereign Wealth Fund Minority
CDC Enterprises PE/Buyout Minority
You’re viewing 5 of 14 investors. Get the full list »

Novagali Pharma FAQs

  • When was Novagali Pharma founded?

    Novagali Pharma was founded in 2000.

  • Where is Novagali Pharma headquartered?

    Novagali Pharma is headquartered in Paris, France.

  • What is the size of Novagali Pharma?

    Novagali Pharma has 50 total employees.

  • What industry is Novagali Pharma in?

    Novagali Pharma’s primary industry is Drug Discovery.

  • Is Novagali Pharma a private or public company?

    Novagali Pharma is a Private company.

  • What is the current valuation of Novagali Pharma?

    The current valuation of Novagali Pharma is .

  • What is Novagali Pharma’s current revenue?

    The current revenue for Novagali Pharma is .

  • How much funding has Novagali Pharma raised over time?

    Novagali Pharma has raised $98.3M.

  • Who are Novagali Pharma’s investors?

    123 Investment Managers, Andera Partners, Auriga Partners (Paris), Bpifrance, and CDC Enterprises are 5 of 14 investors who have invested in Novagali Pharma.

  • When was Novagali Pharma acquired?

    Novagali Pharma was acquired on 06-Jan-2012.

  • Who acquired Novagali Pharma?

    Novagali Pharma was acquired by Santen Pharmaceutical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process